The Macro-Vue Card Test (Hynson, Wescott, and Dunning, Baltimore, Md.) for rapid quantitation of gentamicin in serum was compared with bioassay and radioimmunoassay procedures on sera from 100 patients. Regression analysis of paired results from the bioassay (using Klebsiella pneumoniae ATCC 27799) and the Macro-Vue Card Test indicated a correlation coefficient of 0.89, whereas comparing radioimmunoassay and Card Test results yielded a correlation coefficient of 0.83. The bioassay-radioimmunoassay correlation coefficient was 0.88. The data were further examined by grouping the sera of the patients into three categories based on therapeutic concentration ranges as follows: <2 ,ug/ml, subtherapeutic range; 2 to 8 ,ug/ml, therapeutic range; >8 ,ug/ml, potentially toxic range. Of 100 specimen values, 81 fell into the same concentration range when bioassay and Card Test values were compared. Of the 19 disagreements, 12 were considered minor. Of 100 specimen values compared by radioimmunoassay and the Card Test, 88 fell into the same concentration range. Of the 12 disagreements, 6 were considered minor. Therefore, the Macro-Vue Card Test for gentamicin compared favorably with both the bioassay and radioimmunoassay procedures. The minimal time required to perform the Card Test (12 to 15 min) makes it attractive for situations in which immediate results are needed.
The Macro-Vue Card Test (Hynson, Wescott, and Dunning, Baltimore, Md.) for rapid quantitation of gentamicin in serum was compared with bioassay and radioimmunoassay procedures on sera from 100 patients. Regression analysis of paired results from the bioassay (using Klebsiella pneumoniae ATCC 27799) and the Macro-Vue Card Test indicated a correlation coefficient of 0.89, whereas comparing radioimmunoassay and Card Test results yielded a correlation coefficient of 0.83. The bioassay-radioimmunoassay correlation coefficient was 0.88. The data were further examined by grouping the sera of the patients into three categories based on therapeutic concentration ranges as follows: <2 ,ug/ml, subtherapeutic range; 2 to 8 ,ug/ml, therapeutic range; >8 ,ug/ml, potentially toxic range. Of 100 specimen values, 81 fell into the same concentration range when bioassay and Card Test values were compared. Of the 19 disagreements, 12 were considered minor. Of 100 specimen values compared by radioimmunoassay and the Card Test, 88 fell into the same concentration range. Of the 12 disagreements, 6 were considered minor. Therefore, the Macro-Vue Card Test for gentamicin compared favorably with both the bioassay and radioimmunoassay procedures. The minimal time required to perform the Card Test (12 to 15 min) makes it attractive for situations in which immediate results are needed.
Several different procedures are available to monitor gentamicin levels, including bioassay (4, 5), radioimmunoassay (RIA) (2, 4, 5), radioenzymatic assay (2, 4) , and enzyme immunoassays (4, 5) . These methods are all acceptable procedures for the measurement of gentamicin. However, they require relatively expensive equipment for performance of the assays.
The Macro-Vue Card Test (Hynson, Wescott, and Dunning, Baltimore, Md.) is designed to provide reproducible results without the necessity for sophisticated equipment and to enable most laboratories to monitor gentamicin serum levels quickly.
The purpose of this study was to evaluate the Macro-Vue Card Test for accuracy and technical facility by comparison with the bioassay and radioimmunoassay procedures on sera from patients.
( 0.3, 0.4, 0.5, and 0.6 ,ug of gentamicin per ml were also placed on the test card. Antigentamicin antiserum was added to each well, enabling the gentamicin present in the serum dilutions and in the standards to react with the antibody. Gentamicin-coated latex particles were then added to all of the wells on the card, which was put on a rotator at 100 rpm for 8 min. After mechanical mixing, the card was held under a high-intensity lamp, and the presence or absence of agglutination (clumping) was determined for the standards and the sera from patients. The lowest concentration of the standard showing complete inhibition of agglutination was multiplied by the reciprocal of the highest dilution of the test specimen demonstrating complete inhibition to determine the concentration of gentamicin in the test specimen. One card containing 12 wells for specimen dilutions and 4 wells for standards was needed per serum sample tested.
Statistical analysis. Bioassay, RIA, and the MacroVue Card Test were each performed by different individuals without knowledge of the other test results. Linear regression analysis was used to determine the coefficients of correlation for RIA-bioassay, bioassay-Macro-Vue Test, and RIA-Macro-Vue Test comparisons.
RESULTS
A total of 100 sera from patients were tested with the Macro-Vue Card Test, the K. pneumoniae ATCC 27799 agar diffusion bioassay, and a commercially available RIA procedure. Linear regression analysis of paired results from the Card Test and bioassay indicated a correlation coefficient of 0.89 (Fig. 1) . Similar results were noted in comparing the paired values for bioassay and RIA, in which a correlation coefficient of 0.88 was noted (Fig. 2) The data were further examined by grouping them into three categories based upon therapeutic concentration ranges as follows: <2 pg/ml, subtherapeutic range; 2 to 8 ,ug/ml, therapeutic range; and >8 ,ug/ml, potentially toxic range. Of 100 specimens compared by the Macro-Vue and bioassay data, 81 fell into the same concentration range (Fig. 4) . Those tests completely agreeing and their respective concentration ranges can be seen by reading Fig. 4 (Fig. 5) . Six of the tests were considered to be significantly different, resulting in 94% overall agreement.
DISCUSSION
Numerous studies have demonstrated the value of the RIA method for determination of gentamicin levels (2, (4) (5) (6) . In a study by Standiford et al. (6) (Fig. 4 and 5) , only 6 to 7% of the specimens did not fall into the appropriate therapeutic concentration range, indicating that the Card Test results are still of clinical value the vast majority of the time.
The Macro-Vue Card Test was most difficult to interpret with serum specimens containing less than 2 ,ug of gentamicin per ml, an observation which was also noted in a previous study (6) . At the lower dilutions, it became quite difficult to interpret complete inhibition of agglutination. In specimens containing >2 ,ug of gentamicin per ml, the endpoint was much easier to see.
Overall, the Macro-Vue Card Test is simple to perform and rapid (15 min). The test compares favorably with the RIA and bioassay procedures. Therefore, we feel the Macro-Vue Gentamicin Card Test is useful for determination of gentamicin levels in human serum for laboratories in which small numbers of specimens are run and in those situations where immediate results are needed.
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